Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
about
Competing Visions of the Implications of Neuroscience for PsychotherapyEvaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.Syncopal episodes associated with cisapride and concurrent drugs.The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.Treatment-resistant depression in late life.Behavioral disturbances of dementia.Dementia with Lewy bodies: review and pharmacotherapeutic implications.Psychotropic drugs and falls: new evidence pertaining to serotonin reuptake inhibitors.Citalopram in the treatment of depression.Coadministration of short-term zolpidem with sertraline in healthy women.Pindolol augmentation of antidepressants: a review and rationale.Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?The use of antidepressant and antipsychotic drugs in elderly epilepsy patients.Fluoxetine in the treatment of premenstrual dysphoric disorder.Citalopram-induced severe hyponatraemia with coma and seizure. Case report with literature and spontaneous reports review.Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.Paroxetine: current status in psychiatry.Sex differences in pharmacokinetics of antidepressants.Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety.Hot flushes in women with breast cancer: state of the art and future perspectives.Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives.Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine.Pharmacokinetics of antidepressants in patients with hepatic impairment.Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies.Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.Drug Interactions in Neurocritical Care.Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells.Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.Comparing episodes of antidepressants use with intermittent episodes of no use: A higher relative risk of suicide attempts but not of suicide at young age.Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions.Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury.The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.RD-Metabolizer: an integrated and reaction types extensive approach to predict metabolic sites and metabolites of drug-like molecules.
P2860
Q29028850-65EFA67E-52D0-4D9C-A017-B0D51B933E4FQ32039141-550EE54B-AC91-48AB-8162-90432D60DDDAQ32049802-EF7E436B-E1DA-4FE0-B5D4-B186CC814B5CQ33175671-AB3817FA-6F42-40A6-8A0F-BA5BA92A74DBQ33181987-C30AF99D-9070-4DD0-BB6A-760BDFA4D823Q33254664-68D35925-0286-4042-B7DF-359506D8423AQ33609576-B8F51802-4E4E-453D-A0C8-3DE13A45D81BQ33609591-933EDA58-1938-4578-9AFC-0DF970C76283Q33693803-03A8763F-E917-495C-B3EC-BCECAC896CF4Q33871483-51B842D2-2AED-44D3-AF9F-A3000F21FB36Q33946527-7D5A0E6B-27D6-4666-B86F-F288A027CEDCQ33954774-4BD6689C-FF81-4547-BA60-DBDAD526EB9DQ34143604-857C7724-E0B0-4966-8B80-C26A053C0FC7Q34146983-51353884-BB7C-4487-8FA0-549BF0A39159Q34570611-A5B1FB9B-6C66-4793-A7F9-061E8B948310Q34579655-B08C3876-9CED-43C9-8541-B9228F26CC00Q35034861-57ED422F-F6AC-4B16-9E85-B52507B76267Q35097430-B04472BF-1FAE-4FB4-BFD6-0A1A325589F0Q36053702-6019F68C-9170-41B0-A3B6-DD5C0C6E8095Q36637666-758435AC-DCCC-4944-B225-12DD20CF9D14Q36678655-050A6D5B-447F-41CA-A53C-5EF9D0DB77C0Q36730643-43B4F44D-5E62-4F68-B986-DF82A166325DQ37824711-B36D5071-6E20-4DA9-8CCC-94A2850B8B8BQ37830040-42BE59D4-2149-4921-AC76-2E4439DBD596Q38120061-EB325AD1-7DBF-4465-835C-B1EE5759D0C9Q38169220-B65BBA21-6179-4ED7-B357-1D85FC7C9879Q38214488-6C079DF5-70A1-41AB-8058-E4017E7890D9Q38221223-AB8456AA-B03D-4612-B213-B0DF388BB361Q38253564-D6E7152B-3C3D-40E1-8C2D-60D516A99A39Q38781285-9E64DC17-3217-431B-99AE-3FB292D694B9Q38831882-AC16485C-5FCC-40B1-8663-045275C736A8Q39067987-ADC28D4F-6B8F-4B7F-9075-FA3BE30D3A26Q39218780-8B6B7F72-E208-48E1-819B-2C16ACD26712Q40764468-CAFF6A27-38CA-4BDC-AC57-DA56CD9C667DQ40838252-93E1F2E8-6087-4785-A0E8-1D377CC8902FQ40842828-4A944130-B958-484D-9204-5982EF871468Q41432957-C1604534-30E1-44E1-A9D2-4AB6CD678EBDQ42011215-BBCA319B-78AE-4BBC-BFE0-FC16A232BC57Q42599261-FEF83DBA-79B1-4366-863E-6CFABF9DBA11Q42931522-5AE566A1-0AEE-4EFC-8295-8D7AA029762A
P2860
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
description
im Januar 1997 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в 1997
@uk
name
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@en
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@nl
type
label
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@en
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@nl
prefLabel
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@en
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@nl
P1476
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
@en
P2093
Sheldon H. Preskorn
P356
10.2165/00003088-199700321-00003
P433
Supplement 1
P577
1997-01-01T00:00:00Z
P6179
1028947410